Patent US4822606A successfully refreshed from Google Patents.
US4822606A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Immunosuppressive synthetic peptides and analogs thereof based on retroviral envelope sequences
Assignee: Duke University
•
Filing: 1986-04-07
•
Granted: 1989-04-18
•
Expires: 2006-04-07
Abstract
Abstract Novel peptides having immunosuppressive or immunoregulatory activity are disclosed.
Inventors
- 👤 Ralph D. Snyderman
- 👤 George J. Cianciolo
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-05 11:18
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/005; A; A61; A61K; A61K38/00; C12; C12N; C12N2740/00; C12N2740/00011; C12N2740/10011; C12N2740/14011; C12N2740/14022; Y; Y10; Y10S; Y10S930/00; Y10S930/01; Y10S930/22; Y10S930/221
Claims Analysis
Total Claims: 44
Claim 1
Independent Claim
101 words
A peptide having immunosuppressive or immunoregulatory activity, comprising the formula (I): A-Gln-B-Arg-C-D-E-F-G-H-I-J-K-L-M-N-O wherein: A is Leu, Ala or Tyr; B is Asn or Ala; C is Arg, Leu or Ile; D is Gly, Ala or Leu; E is Leu or Ala; F is Asp or Val; G is Leu, Tyr, Glu or Ile; H is Leu or Arg; I is Phe, Leu, Tyr or Thr; J is Leu, Trp or Ala; K is Lys, Glu, Gln or Ala; L is Glu, Gln or Asp; M is Gly or Gln; N is Gly or Gln; and O is Leu, Val or Ile.
Claim 2
Dependent Claim
101 words
A peptide having immunosuppressive or immunoregulatory activity, comprising the formula (I): A-Gln-B-Arg-C-D-E-F-G-H-I-J-K-L-M-N-O wherein: A is Leu, Ala or Tyr; B is Asn or Ala; C is Arg, Leu or Ile; D is Gly, Ala or Leu; E is Leu or Ala; F is Asp or Val; G is Leu, Tyr, Glu or Ile; H is Leu or Arg; I is Phe, Leu, Tyr or Thr; J is Leu, Trp or Ala; K is Lys, Glu, Gln or Ala; L is Glu, Gln or Asp; M is Gly or Gln; N is Gly or Gln; and O is Leu, Val or Ile.
Claim 3
Dependent Claim
95 words
A peptide having immunosuppressive or immunoregulatory activity, comprising the formula (IV): Gln-B-Arg-C-D-E-F-G-H-I-J-K-L-M-N-O, wherein: B is Asn or Ala; C is Arg, Leu or Ile; D is Gly, Ala or Leu; E is Leu or Ala; F is Asp or Val; G is Leu, Tyr, Glu or Ile; H is Leu or Arg; I is Phe, Leu, Tyr or Thr; J is Leu, Trp or Ala; K is Lys, Glu, Gln or Ala; L is Glu, Gln or Asp; M is Gly or Gln; N is Gly or Gln; and O is Leu, Val or Ile.
Claim 4
Dependent Claim
95 words
A peptide having immunosuppressive or immunoregulatory activity, comprising the formula (IV): Gln-B-Arg-C-D-E-F-G-H-I-J-K-L-M-N-O, wherein: B is Asn or Ala; C is Arg, Leu or Ile; D is Gly, Ala or Leu; E is Leu or Ala; F is Asp or Val; G is Leu, Tyr, Glu or Ile; H is Leu or Arg; I is Phe, Leu, Tyr or Thr; J is Leu, Trp or Ala; K is Lys, Glu, Gln or Ala; L is Glu, Gln or Asp; M is Gly or Gln; N is Gly or Gln; and O is Leu, Val or Ile.
Claim 5
Dependent Claim
15 words
The peptide of claim 1, wherein the said peptide is coupled to a carrier protein.
Claim 6
Dependent Claim
15 words
The peptide of claim 2, wherein the said peptide is coupled to a carrier protein.
Claim 7
Dependent Claim
20 words
The peptide of claim 1, wherein the said peptide is coupled to a protein to be rendered nonimmunogenic or tolerogenic.
Claim 8
Dependent Claim
20 words
The peptide of claim 2, wherein the said peptide is coupled to a protein to be rendered nonimmunogenic or tolerogenic.
Claim 9
Dependent Claim
11 words
The peptide of claim 1, said peptide having the formula: Leu-Gln-Asn-Arg-Arg-Gly-Leu-Asp-Leu-Leu-Phe-Leu-Lys-Glu-Gly-Gly-Leu.
Claim 10
Dependent Claim
11 words
The peptide of claim 1, said peptide having the formula: Ala-Gln-Asn-Arg-Arg-Gly-Leu-Asp-Leu-Leu-Phe-Trp-Glu-Gln-Gly-Gly-Leu.
Claim 11
Dependent Claim
11 words
The peptide of claim 1, said peptide having the formula: Tyr-Gln-Asn-Arg-Leu-Ala-Leu-Asp-Tyr-Leu-Leu-Ala-Ala-Glu-Gly-Gly-Val.
Claim 12
Dependent Claim
11 words
The peptide of claim 1, said peptide having the formula: Leu-Gln-Ala-Arg-Ile-Leu-Ala-Val-Glu-Arg-Tyr-Leu-Lys-Asp-Gln-Gln-Leu.
Claim 13
Dependent Claim
11 words
The peptide of claim 1, said peptide having the formula: Leu-Gln-Asn-Arg-Arg-Gly-Leu-Asp-Leu-Leu-Thr-Ala-Glu-Gln-Gly-Gly-Ile.
Claim 14
Dependent Claim
149 words
A peptide having immunosuppressive or immunoregulatory activity, comprising the formula: D-E-F-G-H-I-J-K-L-M-N-O-P-Q-R-S-T-U-V-W-X-Y wherein: D is Gly, Ala or Leu; E is Leu or Ala; F is Asp or Val; G is Leu, Tyr, Glu or Ile; H is Leu or Arg; I is Phe, Leu, Tyr or Thr; J is Leu, Trp or Ala; K is Lys, Glu, Gln or Ala; L is Glu, Gln or Asp; M is Gly or Gln; N is Gly or Gln; O is Leu, Val or Ile; P is Cys or Leu; Q is Ala, Lys, Gly or Leu; R is Ala, Lys or Ile; S is Leu, Ile, Phe or Trp; T is Lys, Gln, Gly or Asn; U is Glu, Leu or Cys; V is Glu, Gln, Thr, Ser or Lys; W is Cys, Asn or Gly; X is Cys, Arg, Phe, Tyr or Lys; and Y is Phe, Cys or Leu.
Claim 15
Dependent Claim
149 words
A peptide having immunosuppressive or immunoregulatory activity, comprising the formula: D-E-F-G-H-I-J-K-L-M-N-O-P-Q-R-S-T-U-V-W-X-Y wherein: D is Gly, Ala or Leu; E is Leu or Ala; F is Asp or Val; G is Leu, Tyr, Glu or Ile; H is Leu or Arg; I is Phe, Leu, Tyr or Thr; J is Leu, Trp or Ala; K is Lys, Glu, Gln or Ala; L is Glu, Gln or Asp; M is Gly or Gln; N is Gly or Gln; O is Leu, Val or Ile; P is Cys or Leu; Q is Ala, Lys, Gly or Leu; R is Ala, Lys or Ile; S is Leu, Ile, Phe or Trp; T is Lys, Gln, Gly or Asn; U is Glu, Leu or Cys; V is Glu, Gln, Thr, Ser or Lys; W is Cys, Asn or Gly; X is Cys, Arg, Phe, Tyr or Lys; and Y is Phe, Cys or Leu.
Claim 16
Dependent Claim
24 words
The peptide of claim 12, wherein the said peptide is coupled to a carrier protein or a protein to be rendered non-immunogenic or tolerogenic.
Claim 17
Dependent Claim
11 words
The peptide of claim 12, said peptide having the formula: Gly-Leu-Asp-Leu-Leu-Phe-Leu-Lys-Glu-Gly-Gly-Leu-Cys-Ala-Ala-Leu-Lys-Glu-Glu-Cys-Cys-Phe.
Claim 18
Dependent Claim
11 words
The peptide of claim 12, said peptide having the formula: Gly-Leu-Asp-Leu-Leu-Phe-Trp-Glu-Gln-Gly-Gly-Leu-Cys-Lys-Ala-Leu-Gln-Glu-Gln-Cys-Arg-Phe.
Claim 19
Dependent Claim
11 words
The peptide of claim 12, said peptide having the formula: Gly-Leu-Asp-Leu-Leu-Phe-Trp-Glu-Gln-Gly-Gly-Leu-Cys-Lys-Ala-Ile-Gln-Glu-Gln-Cys-Cys-Phe.
Claim 20
Dependent Claim
11 words
The peptide of claim 12, said peptide having the formula: Gly-Leu-Asp-Ile-Leu-Phe-Leu-Gln-Glu-Gly-Gly-Leu-Cys-Ala-Ala-Leu-Lys-Glu-Glu-Cys-Cys-Phe.
Claim 21
Dependent Claim
11 words
The peptide of claim 12, said peptide having the formula: Ala-Leu-Asp-Tyr-Leu-Leu-Ala-Ala-Glu-Gly-Gly-Val-Cys-Gly-Lys-Phe-Asn-Leu-Thr-Asn-Tyr-Cys.
Claim 22
Dependent Claim
11 words
The peptide of claim 12, said peptide having the formula: Gly-Leu-Asp-Leu-Leu-Thr-Ala-Glu-Gln-Gly-Gly-Ile-Cys-Leu-Ala-Leu-Gln-Glu-Lys-Cys-Cys-Phe.
Claim 23
Dependent Claim
11 words
The peptide of claim 12, said peptide having the formula: Leu-Ala-Val-Glu-Arg-Tyr-Leu-Lys-Asp-Gln-Gln-Leu-Leu-Gly-Ile-Trp-Gly-Cys-Ser-Gly-Lys-Leu.
Claim 24
Dependent Claim
19 words
A peptide having immunosuppressive or immunoregulatory activity, comprising one of the following amino acid sequence: Gln-Asn-Arg-Leu-Asp-Tyr-Leu-Leu-Ala-Ala-Glu-Gly-Gly-Val-Cys-Gly-Lys-Phe-Asn-Leu-Thr-Asn-Tyr-Cys, Gln-Asn-Arg-Arg-Gly-Leu-Asp-Leu-Leu-Thr-Ala-Glu-Gln-Gly-Gly-Ile-Cys-Leu-Ala-Leu-Gln-Glu-Lys-Cys-Phe, or Gln-Ala-Arg-Ile-Leu-Ala-Val-Glu-Arg-Tyr-Leu-Lys-Asp-Gln-Gln-Leu-Leu-Gly-Ile-Trp-Gly-Cys-Ser-Gly-Lys-Leu.
Claim 25
Dependent Claim
19 words
A peptide having immunosuppressive or immunoregulatory activity, comprising one of the following amino acid sequence: Gln-Asn-Arg-Leu-Asp-Tyr-Leu-Leu-Ala-Ala-Glu-Gly-Gly-Val-Cys-Gly-Lys-Phe-Asn-Leu-Thr-Asn-Tyr-Cys, Gln-Asn-Arg-Arg-Gly-Leu-Asp-Leu-Leu-Thr-Ala-Glu-Gln-Gly-Gly-Ile-Cys-Leu-Ala-Leu-Gln-Glu-Lys-Cys-Phe, or Gln-Ala-Arg-Ile-Leu-Ala-Val-Glu-Arg-Tyr-Leu-Lys-Asp-Gln-Gln-Leu-Leu-Gly-Ile-Trp-Gly-Cys-Ser-Gly-Lys-Leu.
Claim 26
Dependent Claim
34 words
A composite peptide having immunosuppressive activity, comprising one of the following amino acid sequence: Gln-Asn-Arg-Arg-Gly-Leu-Asp-Leu-Leu-Phe-Leu-Lys-Glu-Gly-Gly-Leu-Cys-Ala-Ala-Leu-Lys-Glu-Glu-Cys-Cys-Phe, Gln-Asn-Arg-Arg-Gly-Leu-Asp-Leu-Leu-Phe-trp-Glu-Gln-Gly-Gly-Leu-Cys-Lys-Ala-Leu-Gln-Glu-Gln-Cys-Arg-Phe, or Gln-Asn-Arg-Arg-Gly-Leu-Asp-Leu-Leu-Phe-Trp-Glu-Gln-Gly-Gly-Leu-Cys-Lys-Ala-Ile-Gln-Glu-Gln-Cys-Cys-Phe, coupled to a carrier protein or another protein which is to be rendered non-immunogenic or tolerogenic.
Claim 27
Dependent Claim
34 words
A composite peptide having immunosuppressive activity, comprising one of the following amino acid sequence: Gln-Asn-Arg-Arg-Gly-Leu-Asp-Leu-Leu-Phe-Leu-Lys-Glu-Gly-Gly-Leu-Cys-Ala-Ala-Leu-Lys-Glu-Glu-Cys-Cys-Phe, Gln-Asn-Arg-Arg-Gly-Leu-Asp-Leu-Leu-Phe-trp-Glu-Gln-Gly-Gly-Leu-Cys-Lys-Ala-Leu-Gln-Glu-Gln-Cys-Arg-Phe, or Gln-Asn-Arg-Arg-Gly-Leu-Asp-Leu-Leu-Phe-Trp-Glu-Gln-Gly-Gly-Leu-Cys-Lys-Ala-Ile-Gln-Glu-Gln-Cys-Cys-Phe, coupled to a carrier protein or another protein which is to be rendered non-immunogenic or tolerogenic.
Claim 28
Dependent Claim
14 words
The peptide of claim 22, said peptide comprising the following amino acid sequence: Gln-Asn-Arg-Arg-Gly-Leu-Asp-Leu-Leu-Phe-Leu-Lys-Glu-Gly-Gly-Leu-Cys-Ala-Ala-Leu-Lys-Glu-Glu-Cys-Cys-Phe.
Claim 29
Dependent Claim
14 words
The peptide of claim 22, said peptide comprising the following amino acid sequence: Gln-Asn-Arg-Arg-Gly-Leu-Asp-Leu-Leu-Phe-Trp-Glu-Gln-Gly-Gly-Leu-Cys-Lys-Ala-Leu-Gln-Glu-Gln-Cys-Arg-Phe.
Claim 30
Dependent Claim
14 words
The peptide of claim 22, said peptide comprising the following amino acid sequence: Gln-Asn-Arg-Arg-Gly-Leu-Asp-Leu-Leu-Phe-Trp-Glu-Gln-Gly-Gly-Leu-Cys-Lys-Ala-Ile-Gln-Glu-Gln-Cys-Cys-Phe.
Claim 31
Dependent Claim
11 words
The peptide of claim 21, said peptide having the formula: Gln-Asn-Arg-Leu-Ala-Leu-Asp-Tyr-Leu-Leu-Ala-Ala-Glu-Gly-Gly-Val-Cys-Gly-Lys-Phe-Asn-Leu-Thr-Asn-Tyr-Cys.
Claim 32
Dependent Claim
11 words
The peptide of claim 21, said peptide having the formula: Gln-Asn-Arg-Arg-Gly-Leu-Asp-Leu-Leu-Thr-Ala-Glu-Gln-Gly-Gly-Ile-Cys-Leu-Ala-Leu-Gln-Glu-Lys-Cys-Cys-Phe.
Claim 33
Dependent Claim
11 words
The peptide of claim 21, said peptide having the formula: Gln-Ala-Arg-Ile-Leu-Ala-Val-Glu-Arg-Tyr-Leu-Lys-Asp-Gln-Gln-Leu-Leu-Gly-Ile-Trp-Gly-Cys-Ser-Gly-Lys-Leu.
Claim 34
Dependent Claim
112 words
A composite protein having immuno-suppressive or immuoregulatory activity, said composite protein comprising two peptides comprising the formula (I): A-Gln-B-Arg-C-D-E-F-G-H-I-J-K-L-M-N-O cross-linked to each other, wherein: A is Leu, Ala or Tyr; B is Asn or Ala; C is Arg, Leu or Ile; D is Gly, Ala or Leu; E is Leu or Ala; F is Asp or Val; G is Leu, Tyr, Glu or Ile; H is Leu or Arg; I is Phe, Leu, Tyr or Thr; J is Leu, Trp or Ala; K is Lys, Glu, Gln or Ala; L is Glu, Gln or Asp; M is Gly or Gln; N is Gly or Gln; and O is Leu, Val or Ile.
Claim 35
Dependent Claim
112 words
A composite protein having immuno-suppressive or immuoregulatory activity, said composite protein comprising two peptides comprising the formula (I): A-Gln-B-Arg-C-D-E-F-G-H-I-J-K-L-M-N-O cross-linked to each other, wherein: A is Leu, Ala or Tyr; B is Asn or Ala; C is Arg, Leu or Ile; D is Gly, Ala or Leu; E is Leu or Ala; F is Asp or Val; G is Leu, Tyr, Glu or Ile; H is Leu or Arg; I is Phe, Leu, Tyr or Thr; J is Leu, Trp or Ala; K is Lys, Glu, Gln or Ala; L is Glu, Gln or Asp; M is Gly or Gln; N is Gly or Gln; and O is Leu, Val or Ile.
Claim 36
Dependent Claim
106 words
A composite protein having immunosuppressive or immunoregulatory activity, said composite protein comprising two peptides comprising the formula (IV): Gln-B-Arg-C-D-E-F-G-H-I-J-K-L-M-N-O cross-linked to each other, wherein: B is Asn or Ala; C is Arg, leu or Ile; D is Gly, Ala or Leu; E is Leu or Ala; F is Asp or Val; G is Leu, Tyr, Glu or Ile; H is Leu or Arg; I is Phe, Leu, Tyr or Thr; J is Leu, Trp or Ala; K is Lys, Glu, Gln or Ala; L is Glu, Gln or Asp; M is Gly or Gln; N is Gly or Gln; and O is Leu, Val or Ile.
Claim 37
Dependent Claim
106 words
A composite protein having immunosuppressive or immunoregulatory activity, said composite protein comprising two peptides comprising the formula (IV): Gln-B-Arg-C-D-E-F-G-H-I-J-K-L-M-N-O cross-linked to each other, wherein: B is Asn or Ala; C is Arg, leu or Ile; D is Gly, Ala or Leu; E is Leu or Ala; F is Asp or Val; G is Leu, Tyr, Glu or Ile; H is Leu or Arg; I is Phe, Leu, Tyr or Thr; J is Leu, Trp or Ala; K is Lys, Glu, Gln or Ala; L is Glu, Gln or Asp; M is Gly or Gln; N is Gly or Gln; and O is Leu, Val or Ile.
Claim 38
Dependent Claim
25 words
A composite peptide comprising the amino acid sequence Leu-GLn-Asn-Arg-Arg-Gly-Leu-Asp-Leu-Leu-Phe-Leu-Lys-Glu-Gly-Gly-Leu coupled to a carrier protein or another protein which is to be rendered non-immunogenic or tolerogenic.
Claim 39
Dependent Claim
25 words
A composite peptide comprising the amino acid sequence Leu-GLn-Asn-Arg-Arg-Gly-Leu-Asp-Leu-Leu-Phe-Leu-Lys-Glu-Gly-Gly-Leu coupled to a carrier protein or another protein which is to be rendered non-immunogenic or tolerogenic.
Claim 40
Dependent Claim
23 words
The composite peptide of claim 31, wherein the said carrier protein comprises bovine serum albumin, human serum albumin, an immunoglobulin or a hormone.
Claim 41
Dependent Claim
19 words
The composite peptide of claim 31, wherein the said carrier protein comprises bovine serum albumin or human serum albumin.
Claim 42
Dependent Claim
15 words
The composite peptide of claim 31, wherein the said carrier protein comprises human serum albumin.
Claim 43
Dependent Claim
36 words
A composite peptide having immunosuppressive or immunoregulatory activity, comprising one of the following amino acid sequences: Gln-Asn-Arg-Leu-Ala-Leu-Asp-Tyr-Leu-Leu-Ala-Ala-Glu-Gly-Gly-Val-Cys-Gly-Lys-Phe-Asn-Leu-Thr-Asn-Tyr-Cys; Gln-Asn-Arg-Arg-Gly-Leu-Asp-Leu-Leu-Thr-Ala-Glu-Gln-Gly-Gly-Ile-Cys-Leu-Ala-Leu-Gln-Glu-Lys-Cys-Cys-Phe; or Gln-Ala-Arg-Ile-Leu-Ala-Val-Glu-Arg-Tyr-Leu-Lys-Asp-Gln-Gln-Leu-Leu-Gly-Ile-Trp-Gly-Cys-Ser-Gly-Lys-Leu, coupled to a carrier protein or another protein which is to be rendered non-immunogenic or tolerogenic.
Claim 44
Dependent Claim
36 words
A composite peptide having immunosuppressive or immunoregulatory activity, comprising one of the following amino acid sequences: Gln-Asn-Arg-Leu-Ala-Leu-Asp-Tyr-Leu-Leu-Ala-Ala-Glu-Gly-Gly-Val-Cys-Gly-Lys-Phe-Asn-Leu-Thr-Asn-Tyr-Cys; Gln-Asn-Arg-Arg-Gly-Leu-Asp-Leu-Leu-Thr-Ala-Glu-Gln-Gly-Gly-Ile-Cys-Leu-Ala-Leu-Gln-Glu-Lys-Cys-Cys-Phe; or Gln-Ala-Arg-Ile-Leu-Ala-Val-Glu-Arg-Tyr-Leu-Lys-Asp-Gln-Gln-Leu-Leu-Gly-Ile-Trp-Gly-Cys-Ser-Gly-Lys-Leu, coupled to a carrier protein or another protein which is to be rendered non-immunogenic or tolerogenic.
References Cited (Backward Citations)
EP0114759A2
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1992-04-17 | 1992-10-17 | 1993-04-18 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1996-04-17 | 1996-10-17 | 1997-04-18 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2000-04-17 | 2000-10-17 | 2001-04-18 | $7700.00 | Window Closed / Lapsed |